384 results on '"Lu, Hailing"'
Search Results
2. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
3. Pathogenesis-related protein-4 (PR-4) gene family in Qingke (Hordeum vulgare L. var. nudum): genome-wide identification, structural analysis and expression profile under stresses
4. A method based on the conversion and determination of folpet and phthalimide residues in tea by GC-MS/MS and GC-TOF-HRMS
5. Comparative physiological and transcriptomic analysis of sesame cultivars with different tolerance responses to heat stress
6. Author Correction: MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
7. Leader Humor Extends beyond Work: how and when Followers Have Better Family Lives
8. Advances in the treatment of IgA nephropathy with biological agents
9. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma
10. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC
11. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1
12. The vitamin E analog alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
13. 699 Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with metastatic non-small cell lung cancer or metastatic cutaneous melanoma after progression on anti-PD-1 therapy
14. 1155 Activated regulatory T cells in solid tumors express CD30, which are selectively targeted by the novel anti-CD30 antibody drug conjugate SGN-35T
15. Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma
16. Employability and job search behavior : A six-wave longitudinal study of Chinese university graduates
17. Advances in the treatment of IgA nephropathy with biological agents
18. Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling
19. Abstract 3253: CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors
20. Table S2 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
21. Supplementary Figure 5 from TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
22. Supplementary Table 1 from TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
23. Table S2 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
24. Figure S2 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
25. Figure S1 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
26. Supplementary Figure 3 from TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
27. Supplementary Figure 4 from VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
28. Supplementary Figure 2 from TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
29. Supplementary Figure 1 from TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
30. Data from Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells
31. Supplementary Data from Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells
32. Supplementary Figure 2 from VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
33. Supplementary Figure 1 from VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
34. Supplementary Figure 4 from TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
35. Supplementary Figure 3 from VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
36. USP22 promotes tumor progression and induces epithelial–mesenchymal transition in lung adenocarcinoma
37. Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
38. Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
39. miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC
40. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway
41. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
42. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer
43. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant
44. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient
45. The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan
46. Apatinib plus etoposide as second-or higher-line treatment in recurrent or metastatic triple-negative breast cancer: A single-arm, open label, prospective, phase II clinical trial.
47. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
48. miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells
49. Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
50. Research and application of medium to low voltage cable tunnel monitoring system based on NB-IoT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.